These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24691494)

  • 21. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).
    Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S
    BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A peer support programme for enhancing adherence to oral antipsychotic medication in consumers with schizophrenia.
    Boardman G; McCann T; Kerr D
    J Adv Nurs; 2014 Oct; 70(10):2293-302. PubMed ID: 24628395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia.
    Hudson TJ; Owen RR; Thrush CR; Armitage TL; Thapa P
    J Clin Psychiatry; 2008 Jan; 69(1):74-80. PubMed ID: 18312040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).
    Miyaoka T; Furuya M; Horiguchi J; Wake R; Hashioka S; Tohyama M; Mori N; Minabe Y; Iyo M; Ueno S; Ezoe S; Murotani K; Hoshino S; Seno H
    Psychopharmacology (Berl); 2015 Jan; 232(1):155-64. PubMed ID: 24923986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
    Gharabawi GM; Greenspan A; Rupnow MF; Kosik-Gonzalez C; Bossie CA; Zhu Y; Kalali AH; Awad AG
    BMC Psychiatry; 2006 Oct; 6():45. PubMed ID: 17054789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
    Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
    Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
    Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
    Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS).
    Farooq S; Nazar Z; Irfan M; Akhter J; Gul E; Irfan U; Naeem F
    Br J Psychiatry; 2011 Dec; 199(6):467-72. PubMed ID: 22130748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial.
    Priebe S; Bremner SA; Lauber C; Henderson C; Burns T
    Health Technol Assess; 2016 Sep; 20(70):1-122. PubMed ID: 27682868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial.
    Chien WT; Mui J; Gray R; Cheung E
    BMC Psychiatry; 2016 Feb; 16():42. PubMed ID: 26911397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
    Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R
    Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
    Koblan KS; Kent J; Hopkins SC; Krystal JH; Cheng H; Goldman R; Loebel A
    N Engl J Med; 2020 Apr; 382(16):1497-1506. PubMed ID: 32294346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
    Potkin SG; Cohen M; Panagides J
    J Clin Psychiatry; 2007 Oct; 68(10):1492-500. PubMed ID: 17960962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, placebo-controlled study of F17464, a preferential D
    Bitter I; Lieberman JA; Gaudoux F; Sokoloff P; Groc M; Chavda R; Delsol C; Barthe L; Brunner V; Fabre C; Fagard M; Montagne A; Tonner F
    Neuropsychopharmacology; 2019 Oct; 44(11):1917-1924. PubMed ID: 30822774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.